

WEIL FENG

Counsel
Fangda Partners
+86 10 5769 5644
weil.feng@fangdalaw.com



PRACTICE AREAS

MR. FENG SPECIALIZES IN M&A, PRIVATE EQUITY, VENTURE CAPITAL AND OVERSEAS CAPITAL MARKETS. HIS MAIN PRACTICE INDUSTRIES INCLUDE TMT, NEW PHARMACUETICALS, AND NEW ENERGY.

REPRESENTATIVE MATTERS AND CASES

M&A

- Represented the buyers consortium comprised of the management, Alibaba, IDG and certain other investors as the U.S. legal counsel and lead counsel in the privatization of BEST Inc.
- Represented VIPTHINK in its merger with another leading online education company in the Cayman Islands and a simultaneous USD 100 million financing led by Soft Bank
- Represented Central Huijin in risk mitigation transactions, including its RMB 60 billion strategic investment in a controlling stake in Hengfeng Bank, forming Zhonghui Life Insurance with China Insurance Security Fund Co., Ltd. to acquire substantially all assets of Tianan Life Insurance in an RMB 33 billion transaction, and in a share transfer project involving an extremely large national asset management company
- Represented Boyu Capital in the reorganization of two leading drink distribution companies and its RMB 400 million strategic investment in the restructured entity. This deal involved complicated exclusive licensing arrangements, deal structures and arrangements for the simultaneous financing of the parent and the subsidiary as well as complex litigation and arbitration with competitors
- Represented BGP INC., China National Petroleum Corporation in its acquisition of all equity interests in INOVA held by ION, which was delisted

from the New York Stock Exchange and was liquidated in the U.S.

- Represented Rambus Ltd. in the sale of all its equity interests in Hefei Reliance
- Assisted China Baowu Group in its joint venture with Shandong Xinhai Technology and Vale S.A. for the construction and development of an RKEF nickel processing facility in Sulawesi
- Represented Ping An Technology in its sale of a 49% equity interest in a joint venture with SoftBank in Japan and in its renegotiation of IP licenses and R&D transactions
- Represented HKSE-listed Hundsun in its joint venture with a Singapore technology company in Hong Kong
- Represented Kingsoft Cloud in its acquisition of Yunfan Jiasu, a leading edge cloud service provider in China. This deal involved complex structuring and complex cross-border foreign exchange and tax issues
- Represented an internet giant in its potential acquisition of two NEV companies, including conducting legal due diligence, analyzing the NEV company's licenses and permits, and structuring the transaction

PRIVATE EQUITY AND VENTURE CAPITAL

- Represented Tiger Global, Vision Plus and SIG in investments across multiple jurisdictions, including China, the Cayman Islands, the U.S. and Singapore
- Represented CICC Capital in its investments in Baichuan AI, Moonshot, Lianlian Pay, Yunxi Technology and CITIC Dicastal
- Represented Qingcheng Tech and Seetrum in their respective angel financing
- Represented Taikang in equity investments (including material equity investment transactions) and restructuring transactions, including the acquisition of Xunzheng Medicine, the investment in Antengene, the red-chip restructuring of Butong Group and the investment in SDIC Taikang Trust
- Represented China Mobile Capital in its strategic investment in Haige Communication
- Represented Mafengwo in its USD 80 million series E-1 financing, which was a down-round financing extensively negotiated with the investor and the existing shareholders
- Represented NeoNexus Group, a top chip design firm, in its Series A financing from top-tier market investors

- Represented HKSE-listed 3SBio in its strategic equity investment in Numab Therapeutics AG, a pharmaceutical company incorporated and operated in Switzerland, and in its obtaining exclusive license to new drug patents from Numab Therapeutics AG
- Represented CPE in its equity investment in Roivant China Sciences Ltd., a company founded by Roivant Sciences Ltd to primarily engage in research, development and commercialization of new drugs in the greater China area
- Represented Huagai Capital in its investment in Synaptic Medical International, a leading electrophysiological medical devices company
- Represented Tao Che, an auto trading platform split from by Yixin Group, in its RMB 500 million Series B financing

OVERSEAS CAPITAL MARKETS

- Representing a leading cross-border e-commerce company in its potential listing in the U.S.
- Represented issuers and underwriters in several U.S. IPO deals, including the initial public offering ADs of Xpeng Inc., Kingsoft Cloud and Tiger Trade (老虎证券)

OTHER INFORMATION

Education

- China University of Political Science and Law, LL.M.
- Wuhan University School of Law, LL.B.

Professional Qualification

- Admitted to practice in the PRC

Work Language

- Mandarin (native)
- English (fluent)

Professional Background

Mr. Feng worked at Fangda from 2017 to 2021 and then rejoined Fangda in 2022 after working at the Beijing office of a leading U.S. law firm from 2021 to 2022.